4/11
08:37 am
ctxr
Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma [Yahoo! Finance]
Low
Report
Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma [Yahoo! Finance]
4/11
08:30 am
ctxr
Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
Low
Report
Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
4/4
08:55 am
ctxr
Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference [Yahoo! Finance]
Low
Report
Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference [Yahoo! Finance]
4/4
08:30 am
ctxr
Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference
Medium
Report
Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference
3/22
09:31 am
ctxr
Thinking about buying stock in Velo3D, Nova Lifestyle, indie Semiconductor, Citius Pharmaceuticals, or Transcode Therapeutics?
Medium
Report
Thinking about buying stock in Velo3D, Nova Lifestyle, indie Semiconductor, Citius Pharmaceuticals, or Transcode Therapeutics?
3/18
08:57 am
ctxr
Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma [Yahoo! Finance]
Low
Report
Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma [Yahoo! Finance]
3/18
08:30 am
ctxr
Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
Medium
Report
Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
3/7
08:41 am
ctxr
Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program [Yahoo! Finance]
Low
Report
Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program [Yahoo! Finance]
3/7
08:30 am
ctxr
Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program
Medium
Report
Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program
2/26
07:45 am
ctxr
Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration [Yahoo! Finance]
Low
Report
Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration [Yahoo! Finance]
2/26
07:30 am
ctxr
Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration
Low
Report
Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration
2/23
08:47 am
ctxr
Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences [Yahoo! Finance]
Medium
Report
Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences [Yahoo! Finance]
2/23
08:30 am
ctxr
Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences
Low
Report
Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences
2/15
09:32 am
ctxr
Citius Pharmaceuticals Inc (CTXR) Reports Q1 2024 Financials and Progress in Clinical Trials [Yahoo! Finance]
Medium
Report
Citius Pharmaceuticals Inc (CTXR) Reports Q1 2024 Financials and Progress in Clinical Trials [Yahoo! Finance]
2/14
04:45 pm
ctxr
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
High
Report
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
2/14
04:30 pm
ctxr
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update
Medium
Report
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update
2/14
02:13 pm
ctxr
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
Low
Report
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
2/14
08:04 am
ctxr
Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma [Yahoo! Finance]
Medium
Report
Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma [Yahoo! Finance]
2/14
08:01 am
ctxr
Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
Medium
Report
Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
2/11
08:30 am
ctxr
Breakeven On The Horizon For Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) [Yahoo! Finance]
Medium
Report
Breakeven On The Horizon For Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) [Yahoo! Finance]